Affy Breaks Even, Beats Estimates by 12 Cents a Share | GenomeWeb

NEW YORK, Oct 24 – Affymetrix said Tuesday that it broke even in the third quarter, beating Wall Street’s expectations by 12 cents a share.

The company reported net earnings of $295,000, or zero cents a share on a diluted basis, compared with a net loss of $5.8 million, or 11 cents a share, for the same quarter a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.